本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300049 证券简称：福瑞股份 公告编号：2025-037 内蒙古福瑞医疗科技股份有限公司 2025 年第二次临时股东会决议公告 1、本次股东会未出现否决议案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议； 3、为尊重中小投资者利益，提高中小投资者对公司股东会决议的重大事项的参与度， 本次股东会对中小投资者单独计票。 一、会议召开情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：内蒙古福瑞医疗科技股份有限公司董事会 3、会议召开的合法性、合规性：经公司第八届董事会第十四次会议审议通过，决定 召开 2025 年第二次临时股东会，本次股东会的召开符合有关法律法规、深圳证券交易所 业务规则和公司章程等的规定。 4、会议召开的日期、时间： （1）现场会议时间：2025 年 9 月 17 日（星期三）14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 17 日 9:15~9:25、9:30~11:30、13:00~ ...

北京市嘉源律师事务所 关于内蒙古福瑞医疗科技股份有限公司 2025 年第二次临时股东会的法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 浪管 师事务 所 北京市嘉源律师事务所 关于内蒙古福瑞医疗科技股份有限公司 2025 年第二次临时股东会的法律意见书 嘉源(2025)-04-687 北京市嘉源律师事务所(以下简称"本所")接受内蒙古福瑞医疗科技股份 有限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下 简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股东会规则》") 等现行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规") 以及《内蒙古福瑞医疗科技股份有限公司章程》(以下简称"《公司章程》") 的有关规定,指派本所律师对公司 2025年第二次临时股东会(以下简称"本次 股东会"）进行见证,并依法出具本法律意见书。 为出具本法律意见书,本所指派律师现场见证了本次股东会,查阅了公司提 供的与本次股东会有关的文件和资料,并进行了必要的审查和验证。在前述审查 和验证的过程中,本所律师得到公司的如下承诺和保证:就本所认为出具本法律 意见书所必需审 ...

Core Viewpoint - Furuya Co., Ltd. has shown significant stock price growth in 2023, with a year-to-date increase of 177.74% and a recent surge of 34.83% over the past five trading days [1] Financial Performance - For the first half of 2025, Furuya Co., Ltd. achieved operating revenue of 713 million yuan, representing a year-on-year growth of 11.02%. However, the net profit attributable to shareholders decreased by 31.09% to 51.93 million yuan [2] - The company has distributed a total of 246 million yuan in dividends since its A-share listing, with 52.61 million yuan distributed over the past three years [3] Stock Market Activity - As of September 17, 2023, Furuya Co., Ltd.'s stock price was 87.60 yuan per share, with a market capitalization of 23.212 billion yuan. The stock experienced a trading volume of 874 million yuan and a turnover rate of 4.34% [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on September 15, 2023, where it recorded a net purchase of 74.25 million yuan [1] Shareholder Information - As of August 29, 2023, Furuya Co., Ltd. had 25,600 shareholders, an increase of 6.91% from the previous period. The average number of circulating shares per shareholder was 9,108, a decrease of 6.47% [2] - The top ten circulating shareholders include notable funds such as Huabao Zhongzheng Medical ETF and Ruiyuan Growth Value Mixed A, with varying changes in their holdings [3] Business Overview - Furuya Co., Ltd. specializes in the production and sales of pharmaceuticals in the liver disease sector, as well as the research and sales of medical instruments and services. The revenue composition is as follows: 67.57% from equipment and technology, 27.47% from pharmaceuticals, 4.30% from medical services, and 0.65% from other sources [1]

Core Viewpoint - Furuya Co., Ltd. has shown significant stock price growth in 2023, with a year-to-date increase of 166.30% and a recent surge of 31.98% over the past five trading days [2] Group 1: Stock Performance - As of September 16, Furuya's stock price reached 83.99 CNY per share, with a market capitalization of 22.255 billion CNY [1] - The stock has experienced a 16.28% increase over the past 20 days and a remarkable 167.14% increase over the past 60 days [2] - The company has appeared on the trading leaderboard twice this year, with the latest instance on September 15, where it recorded a net buy of 74.2524 million CNY [2] Group 2: Financial Performance - For the first half of 2025, Furuya reported a revenue of 713 million CNY, reflecting a year-on-year growth of 11.02%, while the net profit attributable to shareholders decreased by 31.09% to 51.934 million CNY [2] - Cumulatively, the company has distributed 246 million CNY in dividends since its A-share listing, with 52.6106 million CNY distributed over the past three years [3] Group 3: Shareholder Information - As of June 30, 2025, Furuya had 25,600 shareholders, an increase of 6.91% from the previous period, with an average of 9,108 circulating shares per shareholder, down by 6.47% [2] - The second-largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 8.7128 million shares, an increase of 947,800 shares from the previous period [3]

证券之星消息，9月15日，生物经济（970038）指数报收于2418.21点，涨0.91%，成交345.84亿元，换手 率2.15%。当日该指数成份股中，上涨的有21家，福瑞股份以20.01%的涨幅领涨，下跌的有29家，华大 基因以3.11%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 13.82% | 239.60 | -0.58% | 2905.01 | r 医药生物 | | sz002252 | 十肖史上 | 4.71% | 6.84 | 0.15% | 454.04 | 医药生物 | | sz300347 | 泰格医药 | 4.69% | 61.77 | 1.25% | 531.86 | 医药生物 | | sz000661 | 长春高新 | 4.34% | 126.81 | 0.88% | 517.31 c | 医药生物 | | sz300759 | 康龙化成 ...

Summary of Key Points Core Viewpoint - The stock of Furuya Co., Ltd. experienced a significant increase, reaching a daily limit up of 20%, with notable trading activity and institutional buying [2][3]. Trading Activity - The stock had a turnover rate of 10.82% and a total trading volume of 1.904 billion yuan, with a price fluctuation of 19.15% throughout the day [2]. - Institutional investors net bought 53.21 million yuan, while the Shenzhen Stock Connect saw a net purchase of 59.96 million yuan [2]. - The top five trading departments accounted for a total transaction volume of 531 million yuan, with net buying of 74.25 million yuan [2]. Institutional Participation - Four institutional special seats were involved in the trading, with total buying amounting to 123 million yuan and selling amounting to 70.16 million yuan, resulting in a net purchase of 53.21 million yuan [2]. - The Shenzhen Stock Connect was the largest buying and selling department, with buying amounting to 129 million yuan and selling amounting to 69.04 million yuan [2]. Fund Flow - The stock saw a net inflow of 344 million yuan from main funds, with large orders contributing 327 million yuan to this inflow [2]. - Over the past five days, the net inflow of main funds totaled 474 million yuan [2]. Margin Trading Data - As of September 12, the margin trading balance for the stock was 1 billion yuan, with a financing balance of 998 million yuan and a securities lending balance of 4.27 million yuan [3]. - In the last five days, the financing balance increased by 41.40 million yuan, representing a growth of 4.33%, while the securities lending balance rose by 0.37 million yuan, a growth of 9.48% [3].

Group 1 - The stock price of Furui Co., Ltd. increased by 13.57%, reaching 77.83 CNY per share, marking a new all-time high [1] - The total market capitalization of the company surpassed 20.623 billion CNY [1] - The trading volume reached 1.159 billion CNY [1]

Core Viewpoint - Furu Pharmaceutical Co., Ltd. has shown a significant stock price increase of 5.18%, reaching 72.08 CNY per share, with a total market capitalization of 19.099 billion CNY as of September 15 [1] Company Overview - Furu Pharmaceutical, established on December 26, 2001, and listed on January 20, 2010, is located in Chaoyang District, Beijing. The company specializes in the production and sales of drugs in the liver disease sector, as well as the research and sales of medical instruments and medical services [1] - The revenue composition of Furu Pharmaceutical is as follows: 67.57% from equipment and technology, 27.47% from pharmaceuticals, 4.30% from medical services, and 0.65% from other sources [1] Fund Holdings - Huaxi Fund has a significant position in Furu Pharmaceutical, with its Huaxi Research Selected Mixed Fund (020444) holding 269,800 shares, accounting for 7.5% of the fund's net value. The fund reduced its holdings by 38,000 shares in the second quarter [2] - The estimated floating profit from this position is approximately 957,800 CNY [2] Fund Performance - The Huaxi Research Selected Mixed Fund (020444) was established on December 28, 2023, with a current size of 117 million CNY. Year-to-date returns are 26.12%, ranking 3,246 out of 8,246 in its category, while the one-year return is 60.27%, ranking 2,186 out of 8,054 [2] - The fund manager, Wu Wenqing, has been in the position for 11 years and 267 days, with the best fund return during his tenure being 102.89% and the worst being -21.1% [3]

Group 1 - The innovative drug concept showed a partial recovery in the afternoon on September 11, with companies like Hotgen Biotech and Furuise Co., Ltd. rising over 10% [2] - Jimin Health achieved a remarkable performance with 6 consecutive trading limits over 12 days, indicating strong market interest [2] - Other companies such as Shutai Shen, Rongchang Biotech, Changshan Pharmaceutical, and Medisi also experienced significant gains, contributing to the overall positive sentiment in the sector [2]

Core Viewpoint - Furu Pharmaceutical Co., Ltd. has seen a stock price increase of 5.38% to 66.38 CNY per share, with a total market capitalization of 17.589 billion CNY as of September 3 [1] Company Overview - Furu Pharmaceutical, established on December 26, 2001, and listed on January 20, 2010, is located in Chaoyang District, Beijing. The company specializes in the production and sales of drugs in the liver disease sector, as well as instrument research and sales, and medical services [1] - The revenue composition of Furu Pharmaceutical is as follows: 67.57% from equipment and technology, 27.47% from pharmaceuticals, 4.30% from medical services, and 0.65% from other sources [1] Shareholder Information - Southern Fund's Southern Medical Health Flexible Allocation Mixed A Fund (000452) is among the top ten circulating shareholders of Furu Pharmaceutical, having increased its holdings by 159,000 shares in the second quarter, totaling 3.8899 million shares, which represents 1.66% of the circulating shares [2] - The fund has achieved a year-to-date return of 55.82%, ranking 462 out of 8,180 in its category, and a one-year return of 55.38%, ranking 2,082 out of 7,967 [2] Fund Manager Performance - The fund manager of Southern Medical Health Flexible Allocation Mixed A Fund is Wang Zhengjiao, who has been in the position for 7 years and 41 days. The fund's total asset size is 2.417 billion CNY, with the best return during Wang's tenure being 74.43% and the worst being -53.83% [3] Fund Holdings - Southern Medical Health Flexible Allocation Mixed A Fund has Furu Pharmaceutical as its sixth-largest holding, with 5.22% of the fund's net value allocated to this stock [4]